Editorial: is pharmacogenetic testing for adverse effects to IBD treatments ready for roll-out?

doi:10.1111/apt.16025

Editorial

. 2020 Sep;52(6):1076-1077.

doi: 10.1111/apt.16025.

Editorial: is pharmacogenetic testing for adverse effects to IBD treatments ready for roll-out?

Desmond Chee^{1

2}, James R Goodhand^{1

2}, Tariq Ahmad^{1

2}

Affiliations

¹ Exeter IBD and Pharmacogenetics Research Group, Exeter, UK.
² Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.

PMID: 33119171
DOI: 10.1111/apt.16025

Editorial

Editorial: is pharmacogenetic testing for adverse effects to IBD treatments ready for roll-out?

Desmond Chee et al. Aliment Pharmacol Ther. 2020 Sep.

. 2020 Sep;52(6):1076-1077.

doi: 10.1111/apt.16025.

Authors

Desmond Chee^{1

2}, James R Goodhand^{1

2}, Tariq Ahmad^{1

2}

Affiliations

¹ Exeter IBD and Pharmacogenetics Research Group, Exeter, UK.
² Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.

PMID: 33119171
DOI: 10.1111/apt.16025

No abstract available

PubMed Disclaimer

Comment on

Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease.
Bangma A, Voskuil MD, Uniken Venema WTC, Brugge H, Hu S, Lanting P, Franke L, Dijkstra G, Festen EAM, Weersma RK. Bangma A, et al. Aliment Pharmacol Ther. 2020 Jun;51(11):1105-1115. doi: 10.1111/apt.15762. Epub 2020 May 3. Aliment Pharmacol Ther. 2020. PMID: 32363635 Free PMC article.

Cited by

Genotype-protein phenotype characterization of NOD2 and IL23R missense variants associated with inflammatory bowel disease: A paradigm from molecular modelling, dynamics, and docking simulations.
Nasser KK, Shinawi T. Nasser KK, et al. Front Med (Lausanne). 2023 Jan 10;9:1090120. doi: 10.3389/fmed.2022.1090120. eCollection 2022. Front Med (Lausanne). 2023. PMID: 36703890 Free PMC article.

References

REFERENCES

1. Suiter CC, Moriyama T, Matreyek KA, et al. Massively parallel variant characterization identifies NUDT15 alleles associated with thiopurine toxicity. Proc Natl Acad Sci. 2020;117:5394-5401.
1. Heap GA, Weedon MN, Bewshea CM, et al. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet. 2014;46:1131-1134.
1. Walker GJ, Harrison JW, Heap GA, et al. Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease. JAMA. 2019;321:773-785.
1. Sazonovs A, Kennedy NA, Moutsianas L, et al. HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’s disease. Gastroenterology. 2020;158:189-199.
1. Bangma A, Voskuil MD, Uniken Venema WTC, et al. Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease. Aliment Pharmacol Ther. 2020;51:1105-1115.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information

[1] Suiter CC, Moriyama T, Matreyek KA, et al. Massively parallel variant characterization identifies NUDT15 alleles associated with thiopurine toxicity. Proc Natl Acad Sci. 2020;117:5394-5401.

[2] Suiter CC, Moriyama T, Matreyek KA, et al. Massively parallel variant characterization identifies NUDT15 alleles associated with thiopurine toxicity. Proc Natl Acad Sci. 2020;117:5394-5401.

[3] Heap GA, Weedon MN, Bewshea CM, et al. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet. 2014;46:1131-1134.

[4] Heap GA, Weedon MN, Bewshea CM, et al. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet. 2014;46:1131-1134.

[5] Walker GJ, Harrison JW, Heap GA, et al. Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease. JAMA. 2019;321:773-785.

[6] Walker GJ, Harrison JW, Heap GA, et al. Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease. JAMA. 2019;321:773-785.

[7] Sazonovs A, Kennedy NA, Moutsianas L, et al. HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’s disease. Gastroenterology. 2020;158:189-199.

[8] Sazonovs A, Kennedy NA, Moutsianas L, et al. HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’s disease. Gastroenterology. 2020;158:189-199.

[9] Bangma A, Voskuil MD, Uniken Venema WTC, et al. Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease. Aliment Pharmacol Ther. 2020;51:1105-1115.

[10] Bangma A, Voskuil MD, Uniken Venema WTC, et al. Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease. Aliment Pharmacol Ther. 2020;51:1105-1115.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Editorial: is pharmacogenetic testing for adverse effects to IBD treatments ready for roll-out?

Affiliations

Editorial: is pharmacogenetic testing for adverse effects to IBD treatments ready for roll-out?

Authors

Affiliations

Comment on

Similar articles

Cited by

References

REFERENCES

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical